|
English
|
正體中文
|
简体中文
|
總筆數 :0
|
|
造訪人次 :
51885931
線上人數 :
860
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"patnaik a"的相關文件
顯示項目 11-15 / 15 (共2頁)
<< < 1 2
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 臺大學術典藏 |
2020-05-25T07:35:29Z |
Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
|
Chia-Chi Lin; Beeram M; Rowinsky E.K; Takimoto C.H; Ng C.M; Geyer Jr. C.E; Denis L.J; De Bono J.S; Hao D; Tolcher A.W; Rha S.-Y; Jolivet J; Patnaik A. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
|
Ng C.M; Patnaik A; Beeram M; Chia-Chi Lin; Takimoto C.H. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2009 |
Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
|
Tolcher A.W.; Chen H; Dancey J.E; Takimoto C.H; O'Rourke P; Yeh I.-T; Chia-Chi Lin; Calvo E; Papadopoulos K.P; Patnaik A; Sarantopoulos J; Mita A.C; Preston G.G; Mita M.M; Rodon J; Mays T |
顯示項目 11-15 / 15 (共2頁)
<< < 1 2
每頁顯示[10|25|50]項目
|
